{"id":543920,"date":"2021-05-19T23:24:02","date_gmt":"2021-05-19T23:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543920"},"modified":"2021-05-19T23:24:02","modified_gmt":"2021-05-19T23:24:02","slug":"multiple-sclerosis-ms-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-sclerosis-ms-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight_543920.html","title":{"rendered":"Multiple Sclerosis (MS) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621426329.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Multiple Sclerosis (MS) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621426329.png\" alt=\"Multiple Sclerosis (MS) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight has launched a new report on &#8220;<strong>Multiple Sclerosis (MS) &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&rdquo;.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&rsquo;s<\/span><span data-mce-mark=\"1\"> &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Multiple Sclerosis (MS) &ndash; Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>&Prime;<\/span><span data-mce-mark=\"1\"> report delivers an in-depth understanding of the Multiple Sclerosis (MS), historical and forecasted epidemiology as well as the&nbsp; Multiple Sclerosis (MS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Some of the key facts of the Report:<\/span><\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">According to DelveInsight&#8217;s estimates,<\/span><span data-mce-mark=\"1\"> total prevalent population in the 7MM was approximately 1,315,649 in 2017, and is expected to grow for the study period [2017-2028].<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Assessments by <\/span><span data-mce-mark=\"1\">DelveInsight&rsquo;s analysts<\/span><span data-mce-mark=\"1\"> reveal higher prevalence of Multiple Sclerosis in the United States.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Among the European five countries, Germany had the highest prevalent population of Multiple Sclerosis, followed by France. On the other hand, Spain had the lowest prevalent population in 2017. Japan had the lowest prevalent population of Multiple Sclerosis, among the 7MM countries.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">As per the DelveInsight&rsquo;s estimates,<\/span><span data-mce-mark=\"1\"> maximum MS people had relapsing-remitting MS followed by primary progressive MS<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The male-to-female ratio of MS patients differ among various countries, but female excess is a consistent finding. <\/span><span data-mce-mark=\"1\">[As per the DelveInsight&rsquo;s estimates]<\/span><span data-mce-mark=\"1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Key benefits of the report:<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Multiple Sclerosis (MS) market report covers a descriptive overview and comprehensive insight of the Multiple Sclerosis (MS) epidemiology and Multiple Sclerosis (MS) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. The Multiple Sclerosis (MS) market report provides insights on the current and emerging therapies.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. Multiple Sclerosis (MS) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. The Multiple Sclerosis (MS) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Multiple Sclerosis (MS) market.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span>Request for sample pages<\/span><span>:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-market<\/span><\/a><\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metabolic-acidosis-market\"><span><br \/><\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Multiple Sclerosis (MS): Overview<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">The key players involved in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Multiple Sclerosis (MS) market<\/a>:<\/span><\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Novartis<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Merck<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Genentech<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Biogen Idec<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Genzyme<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Biogen Idec Ltd.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Genzyme<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">The launch of the emerging therapies is expected to significantly impact the&nbsp; Multiple Sclerosis (MS) treatment scenario in the upcoming years:-<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Drug covered<\/span><\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Mayzent<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Mavenclad<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ocrevus<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Zinbryta<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Lemtrada<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Plegridy\/Tecfidera<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Aubagio<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span>Request a free sample report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-market<\/span><\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Table of Contents<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. Executive Summary<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. SWOT analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. Multiple Sclerosis (MS) Patient Share (%) Overview at a Glance<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Multiple Sclerosis (MS) Market Overview at a Glance<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. Multiple Sclerosis (MS) Disease Background and Overview<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. Multiple Sclerosis (MS) Epidemiology and Patient Population<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Country-Specific Patient Population of Multiple Sclerosis (MS)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Multiple Sclerosis (MS) Current Treatment and Medical Practices<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Multiple Sclerosis (MS) Emerging Therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. Multiple Sclerosis (MS) Market Outlook<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. Country-Wise Multiple Sclerosis (MS) Market Analysis (2017&ndash;2030)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. Market Access and Reimbursement of Therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. Market drivers<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Market barriers<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. Multiple Sclerosis (MS) Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. About DelveInsight<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Multiple Sclerosis &#8211; Pipeline Insights, 2021<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">&#8220;<\/span><span data-mce-mark=\"1\">Multiple Sclerosis Pipeline Insight, 2021<\/span><span data-mce-mark=\"1\">&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple Sclerosis market. A detailed picture of the Multiple Sclerosis pipeline landscape is provided, which includes the disease overview and&nbsp; Multiple Sclerosis treatment guidelines.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Multiple Sclerosis &#8211; Epidemiology Forecast to 2030<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><span id=\"docs-internal-guid-29ec9351-7fff-e8ef-0268-c015965c7449\">DelveInsight&#8217;s <\/span><span id=\"docs-internal-guid-29ec9351-7fff-e8ef-0268-c015965c7449\">&#8216;Multiple Sclerosis- Epidemiology Forecast to 2030&#8217; <\/span><span id=\"docs-internal-guid-29ec9351-7fff-e8ef-0268-c015965c7449\">report delivers an in-depth understanding of the disease, historical and forecasted Multiple Sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=multiple-sclerosis-ms-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=multiple-sclerosis-ms-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/multiple-sclerosis-ms-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight_543920.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-543920","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543920"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543920\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}